Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

Antzeko izenburuak

• Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi(®))
  nork: Shanmugam, Victoria K., et al.
  Argitaratua: (2013)
• Ruxolitinib for the Treatment of Patients With Polycythemia Vera
  nork: Kiladjian, Jean-Jacques, et al.
  Argitaratua: (2015)
• Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
  nork: Raedler, Lisa
  Argitaratua: (2015)
• Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
  nork: Raedler, Lisa A.
  Argitaratua: (2015)
• Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
  nork: Raedler, Lisa A.
  Argitaratua: (2015)